Mirum Pharmaceuticals (MIRM) Debt to Equity (2020 - 2023)

Mirum Pharmaceuticals' Debt to Equity history runs 4 years deep, the most recent figure standing at $0.01 for Q1 2023.

• In Q1 2023, Debt to Equity fell 57.86% year-over-year to $0.01; the TTM figure through Mar 2023 stood at $0.01 (down 57.86% YoY), while the FY2022 annual figure was $0.01, down 53.78% from the prior year.
• Debt to Equity was $0.01 for Q1 2023 at Mirum Pharmaceuticals, up from $0.01 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.02 in Q2 2021 to a low of $0.01 in Q1 2021.
• Historically, Debt to Equity has averaged $0.01 across 4 years, with a median of $0.01 in 2021.
• The sharpest annual moves came in 2022 and 2023: Debt to Equity soared 163.78% in 2022, then sank 57.86% in 2023.
• A 4-year view of Debt to Equity shows it stood at $0.01 in 2020, then surged by 126.07% to $0.02 in 2021, then slumped by 53.78% to $0.01 in 2022, then advanced by 0.63% to $0.01 in 2023.
• The last three Debt to Equity figures came in at $0.01 (Q1 2023), $0.01 (Q4 2022), and $0.01 (Q3 2022), per Business Quant data.